United Therapeutics (UTHR) Tops Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
United Therapeutics (UTHR) PT Lifted to $195 at Wedbush Posts Q4
February 26, 2015 8:20 AM ESTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on United Therapeutics Corp. (NASDAQ: UTHR) to $195.00 (from $171.00) as Q4 and 2014 top and bottom line beat consensus estimates on strong Adcirca sales.
Moussatos commented, "Reported Q4 / 2014 revenues of $346MM/$1289MM... More
